Can SGLT-2 inhibitors improve cardiovascular outcomes and ensure safety for patients with type 2 diabetes and heart failure in Thailand? A real-world multicentre retrospective cohort study.

ABSTRACT:

Objectives

To assess the real-world effectiveness and safety of sodium-glucose co-transporter-2 inhibitors (SGLT2i) on cardiovascular outcomes in patients with type 2 diabetes mellitus (T2D) and heart failure (HF) and to evaluate the associated risks of adverse events.

Design

A retrospective cohort study using propensity score analysis to control confounding variables.

Setting

Data were collected from the electronic health records of two large tertiary care hospitals in Thailand over a 12-year period (2010-2022).

Participants

Adults aged 18 years and older with a diagnosis of T2D and HF were included in the study. Patients who received SGLT2i for a minimum of 3 months were compared with those in a non-SGLT2i group. Participants with a diagnosis of HF that prece

SUBMITTER: Kongmalai T 

PROVIDER: S-EPMC11647382 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature